Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, CA. Kedalion's AcuStream technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration.